| 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:1615998 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FSCN1 mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | multiple interactions | ISO | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FSCN1 mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | increases expression | ISO | | 6480464 | Ethinyl Estradiol results in increased expression of FSCN1 mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | affects expression | ISO | | 6480464 | Ethinyl Estradiol affects the expression of FSCN1 mRNA | CTD | PMID:17555576 |
| 17alpha-ethynylestradiol | affects expression | ISO | RGD:1615998 | 6480464 | Ethinyl Estradiol affects the expression of FSCN1 mRNA | CTD | PMID:17555576 |
| 17alpha-ethynylestradiol | increases expression | ISO | RGD:1615998 | 6480464 | Ethinyl Estradiol results in increased expression of FSCN1 mRNA | CTD | PMID:17942748 |
| 17beta-estradiol | decreases expression | ISO | RGD:1344433 | 6480464 | Estradiol results in decreased expression of FSCN1 mRNA | CTD | PMID:19167446 |
| 17beta-estradiol | multiple interactions | ISO | RGD:1344433 | 6480464 | [Progesterone co-treated with Estradiol] results in decreased expression of FSCN1 mRNA | CTD | PMID:17404688 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1344433 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of FSCN1 mRNA | CTD | PMID:21632981 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of FSCN1 mRNA | CTD | PMID:15652763 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FSCN1 mRNA | CTD | PMID:17942748 |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1615998 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of FSCN1 mRNA | CTD | PMID:15652763 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1615998 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of FSCN1 mRNA | CTD | PMID:17942748 |
| 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1615998 | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FSCN1 mRNA | CTD | PMID:16054899 |
| 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FSCN1 mRNA | CTD | PMID:16054899 |
| 5-aza-2'-deoxycytidine | affects methylation | ISO | RGD:1344433 | 6480464 | decitabine affects the methylation of FSCN1 gene | CTD | PMID:17630775 |
| all-trans-retinoic acid | decreases expression | ISO | RGD:1344433 | 6480464 | Tretinoin results in decreased expression of FSCN1 mRNA | CTD | PMID:15894607 PMID:17218384 |
| benzo[a]pyrene | decreases expression | ISO | | 6480464 | Benzo(a)pyrene results in decreased expression of FSCN1 mRNA | CTD | PMID:19770486 PMID:22228805 |
| benzo[a]pyrene | decreases expression | ISO | RGD:1615998 | 6480464 | Benzo(a)pyrene results in decreased expression of FSCN1 mRNA | CTD | PMID:19770486 PMID:22228805 |
| clofibrate | decreases expression | ISO | | 6480464 | Clofibrate results in decreased expression of FSCN1 mRNA | CTD | PMID:17585979 |
| clofibrate | decreases expression | ISO | RGD:1615998 | 6480464 | Clofibrate results in decreased expression of FSCN1 mRNA | CTD | PMID:17585979 |
| cobalt dichloride | decreases expression | ISO | RGD:1344433 | 6480464 | cobaltous chloride results in decreased expression of FSCN1 mRNA | CTD | PMID:19320972 |
| copper atom | multiple interactions | ISO | RGD:1615998 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSCN1 mRNA | CTD | PMID:15467011 |
| copper atom | multiple interactions | ISO | | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSCN1 mRNA | CTD | PMID:15467011 |
| copper(0) | multiple interactions | ISO | RGD:1615998 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSCN1 mRNA | CTD | PMID:15467011 |
| copper(0) | multiple interactions | ISO | | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of FSCN1 mRNA | CTD | PMID:15467011 |
| coumestrol | multiple interactions | ISO | RGD:1344433 | 6480464 | [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FSCN1 mRNA | CTD | PMID:19167446 |
| cyclophosphamide | increases expression | ISO | RGD:1344433 | 6480464 | Cyclophosphamide results in increased expression of FSCN1 mRNA | CTD | PMID:17403535 |
| cyclosporin A | decreases expression | ISO | RGD:1344433 | 6480464 | Cyclosporine results in decreased expression of FSCN1 mRNA | CTD | PMID:20106945 PMID:21632981 |
| dexamethasone | multiple interactions | ISO | RGD:1615998 | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FSCN1 mRNA | CTD | PMID:16054899 |
| dexamethasone | multiple interactions | ISO | | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FSCN1 mRNA | CTD | PMID:16054899 |
| diarsenic trioxide | decreases expression | ISO | RGD:1344433 | 6480464 | arsenic trioxide results in decreased expression of FSCN1 mRNA | CTD | PMID:15070760 more ... |
| dibutyl phthalate | decreases expression | ISO | RGD:1615998 | 6480464 | Dibutyl Phthalate results in decreased expression of FSCN1 mRNA | CTD | PMID:21266533 |
| dibutyl phthalate | decreases expression | ISO | | 6480464 | Dibutyl Phthalate results in decreased expression of FSCN1 mRNA | CTD | PMID:21266533 |
| lovastatin | decreases expression | ISO | RGD:1615998 | 6480464 | Lovastatin results in decreased expression of FSCN1 mRNA | CTD | PMID:20493250 |
| lovastatin | decreases expression | ISO | | 6480464 | Lovastatin results in decreased expression of FSCN1 mRNA | CTD | PMID:20493250 |
| paclitaxel | increases response to substance | ISO | RGD:1344433 | 6480464 | FSCN1 protein results in increased susceptibility to Paclitaxel | CTD | PMID:16734730 |
| perfluorooctanoic acid | decreases expression | ISO | RGD:1344433 | 6480464 | perfluorooctanoic acid results in decreased expression of FSCN1 protein | CTD | PMID:22609092 |
| phorbol 13-acetate 12-myristate | multiple interactions | ISO | RGD:1615998 | 6480464 | FSCN1 mutant form affects the expression of [Tetradecanoylphorbol Acetate results in increased expression of TNF protein] | CTD | PMID:22102721 |
| phorbol 13-acetate 12-myristate | increases expression | ISO | | 6480464 | Tetradecanoylphorbol Acetate results in increased expression of FSCN1 mRNA | CTD | PMID:22102721 |
| phorbol 13-acetate 12-myristate | multiple interactions | ISO | | 6480464 | FSCN1 mutant form affects the expression of [Tetradecanoylphorbol Acetate results in increased expression of TNF protein] | CTD | PMID:22102721 |
| phorbol 13-acetate 12-myristate | increases expression | ISO | RGD:1615998 | 6480464 | Tetradecanoylphorbol Acetate results in increased expression of FSCN1 mRNA | CTD | PMID:22102721 |
| pirinixic acid | increases expression | ISO | RGD:1615998 | 6480464 | pirinixic acid results in increased expression of FSCN1 mRNA | CTD | PMID:18301758 |
| pirinixic acid | increases expression | ISO | | 6480464 | pirinixic acid results in increased expression of FSCN1 mRNA | CTD | PMID:18301758 |
| progesterone | multiple interactions | ISO | RGD:1344433 | 6480464 | [Progesterone co-treated with Estradiol] results in decreased expression of FSCN1 mRNA | CTD | PMID:17404688 |
| quinoline | increases expression | ISO | RGD:1344433 | 6480464 | quinoline analog results in increased expression of FSCN1 protein | CTD | PMID:18645022 |
| rosiglitazone | multiple interactions | ISO | RGD:1615998 | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FSCN1 mRNA | CTD | PMID:16054899 |
| rosiglitazone | multiple interactions | ISO | | 6480464 | [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in decreased expression of FSCN1 mRNA | CTD | PMID:16054899 |
| succimer | multiple interactions | ISO | RGD:1615998 | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of FSCN1 mRNA | CTD | PMID:21641980 |
| succimer | multiple interactions | ISO | | 6480464 | [Succimer binds to Magnetite Nanoparticles] which results in increased expression of FSCN1 mRNA | CTD | PMID:21641980 |
| tamoxifen | affects expression | ISO | RGD:1615998 | 6480464 | Tamoxifen affects the expression of FSCN1 mRNA | CTD | PMID:17555576 PMID:20937368 |
| tamoxifen | affects expression | ISO | | 6480464 | Tamoxifen affects the expression of FSCN1 mRNA | CTD | PMID:17555576 PMID:20937368 |
| tetrachloromethane | affects expression | ISO | | 6480464 | Carbon Tetrachloride affects the expression of FSCN1 mRNA | CTD | PMID:17484886 |
| tetrachloromethane | affects expression | ISO | RGD:1615998 | 6480464 | Carbon Tetrachloride affects the expression of FSCN1 mRNA | CTD | PMID:17484886 |
| troglitazone | increases expression | ISO | RGD:1344433 | 6480464 | troglitazone results in increased expression of FSCN1 mRNA | CTD | PMID:19140230 |
| valproic acid | affects expression | ISO | RGD:1615998 | 6480464 | Valproic Acid affects the expression of FSCN1 mRNA | CTD | PMID:17292431 |
| valproic acid | affects expression | ISO | | 6480464 | Valproic Acid affects the expression of FSCN1 mRNA | CTD | PMID:17292431 |
| vancomycin | decreases expression | ISO | RGD:1615998 | 6480464 | Vancomycin results in decreased expression of FSCN1 mRNA | CTD | PMID:18930951 |
| vancomycin | decreases expression | ISO | | 6480464 | Vancomycin results in decreased expression of FSCN1 mRNA | CTD | PMID:18930951 |
| zoledronic acid | increases expression | ISO | RGD:1344433 | 6480464 | zoledronic acid results in increased expression of FSCN1 mRNA | CTD | PMID:20977926 |